Switch to aflibercept or ranibizumab after initial treatment with bevacizumab in eyes with neovascular AMD

BACKGROUND: To evaluate changes in central macular thickness (CMT) and visual outcome in patients with neovascular age-related macular degeneration (AMD) treated initially with bevacizumab and subsequently switched to either aflibercept or ranibizumab. METHODS: Observational clinical study was perfo...

Descripción completa

Detalles Bibliográficos
Autores principales: Waizel, Maria, Todorova, Margarita G., Masyk, Michael, Wolf, Katharina, Rickmann, Annekatrin, Helaiwa, Khaled, Blanke, Björn R., Szurman, Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5442868/
https://www.ncbi.nlm.nih.gov/pubmed/28535756
http://dx.doi.org/10.1186/s12886-017-0471-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5442868/
https://www.ncbi.nlm.nih.gov/pubmed/28535756
http://dx.doi.org/10.1186/s12886-017-0471-x

Ejemplares similares